 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| SNP318 / SciNeuro Pharma, GSK
Trial completion: A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease (clinicaltrials.gov) - Dec 15, 2023
P1, N=76, Completed, Sponsor: SciNeuro
Active, not recruiting --> Completed
- || SNP318 / SciNeuro Pharma, GSK
Enrollment closed: A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease (clinicaltrials.gov) - Nov 22, 2023
P1, N=86, Active, not recruiting, Sponsor: SciNeuro
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| SNP318 / SciNeuro Pharma, GSK
New P1 trial: A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease (clinicaltrials.gov) - Mar 31, 2023
P1, N=86, Recruiting, Sponsor: SciNeuro